During acute-phase illness, serum of patients with GuillainBarre syndrome (GBS) contain complement-fixing antibodies (Ab) to peripheral nerve myelin (PNM). We investigated PNM lipids as putative antigens for these Ab since GBS serum retained significant reactivity to PNM treated with protease. Ab binding to specific lipids was studied with a C1 fixation and transfer (CFIT) assay using fractions of PNM lipid reincorporated into liposomes as antigen targets or to lipids on HPTLC plates with peroxidase-labeled goat Ab to human IgM. Reactivity was detected to a neutral glycolipid (NGL) of human PNM with a similar number of carbohydrates residues to that of Forssman hapten (Forss). Anti-NGL Ab titers in GBS patients (50-220 U/ml) were significantly elevated over disease and normal controls (0-5 and 0-6 U/ml). We studied possible antigenic cross-reactivity of these Ab with Forss by first quantitating Ab activity with CiFF assay and liposomes containing Forss. All 12 GBS sera tested showed titers (54-272 U/ml) significantly elevated over 11 disease controls (0-22 U/ml) and 25 normal controls (0-11 U/mi). GBS serum Ab reacted with Forss isolated from dog nerve or sheep erythrocytes on HPTLC plates. Further, absorption of 80-100% of anti-NGL Ab activity and 17-97% of anti-PNM Ab activity from eight GBS patient serums was accomplished with liposomes containing Forss but not with control liposomes. In seven GBS patients anti-NGL Ab activity represented only a portion of anti-PNM Ab activity. These results suggest that a glycolipid with antigenic cross-reactivity to Forssman hapten may be responsible for some of the anti-PNM Ab activity in GBS.
Introduction
The Guillain-Barre syndrome (GBS)l is a condition in which transient neurologic symptoms are associated with an inflam-MgCl2; EDTA/VBS, 10 mM EDTA in VBS; GBS, Guillain-Barre Syndrome; GVB2 , VBS with 0.1% gelatin, 0.15 mM CaCl2 and 1.0 mM MgCl2; HPTLC, high performance thin-layer chromatography; NGL, neutral glycolipid; PNM, peripheral nerve myelin; VBS, barbital-buffered saline containing 145 mM NaCl, 5 mM sodium barbital, pH 7.4. matory demyelination of peripheral nerve in which myelin is the target of immune attack (1, 2) . Although details of the mechanism of myelin destruction are not known available evidence suggests that humoral factors, such as Ab and complement are involved. Complement fixing antibodies to peripheral nerve myelin (anti-PNM Ab) can be detected in the serum of GBS patients, and are highest when neurologic symptoms first occur (3) (4) (5) (6) . Clearance of the IgM isotope of these anti-PNM Ab from serum of GBS patients correlates well with the changing clinical status (5, 6) . In addition, the Ab activity in serum of patients correlates with the appearance of the activated products of the terminal complement cascade in serum, cerebrospinal fluid, and peripheral nerve of GBS patients (7) (8) (9) . Plasmapheresis during the first two weeks of disease shortens the clinical course (10) (11) (12) .
Both protein and lipid antigens in PNM are implicated in the production of human and experimental demyelinating neuropathies by Ab reactivity. Monoclonal immunoglobulin of some patients with a paraprotein associated demyelinating neuropathy binds a shared carbohydrate determinant of the myelin-associated glycoprotein (MAG) and unusual sulfoglucuronyl glycosphingolipids of PNM (13) (14) (15) (16) . Serum of these patients demyelinate cat sciatic nerve in the presence of complement (17) . P2 and galactocerebroside both induce experimental neuritis in rats and rabbits (18, 19) . Ab to P2 a basic protein which is not exposed on the myelin surface does not demyelinate explants in vitro (20) while Ab to the surface determinant galactocerebroside causes in vivo and vitro demyelination (21, 22) and mediates cytoxicity of Schwann cells (23) . GBS serum also mediates demyelination in vivo and in vitro (24) (25) (26) . Despite the success in animal models and human paraprotein-associated neuropathy, no consistent Ab reactivity to any of these recognized PNM antigens in GBS is reported (27, 28) . More recently, IgM and/or IgG from 6 of21 GBS patients tested showed binding activity to carbohydrate determinants of a series of PNM and CNM gangliosides separated on a thin-layer chromatography plate (29) . Although these last findings are of interest, no consistent antigen was found and many of the gangliosides bound were shared by both neural and extraneural tissues.
In this study we have evaluated the nature of the PNM lipids as putative antigens for antibody reactivity in GBS serum. Using complement component Cl fixation, immunoabsorption and solid-phase assays, we found that all GBS patients' sera studied contained anti-PNM Ab, which bind to a neutral glycolipid of PNM.
Methods
Collection of clinical material. Serum was collected from patients meeting criteria of the Ad Hoc Committee for GBS (30) during the acute phase of their illness, aliquoted, and stored at -70°C. The clinical and humoral characterization of these sera has been previously described (5, 6, 9). Serum was also obtained from patients with sys-temic lupus erythematosus, rheumatoid arthritis, cancer, paraprotein without neuropathy, poliomyelitis, amyotrophic lateral sclerosis, multiple sclerosis, sarcoidosis, alcoholism, diabetes, as well as other toxic and hereditary neuropathies. Control serum was from healthy laboratory workers.
Buffers. Veronal-buffered saline (VBS) pH 7.4, U = 0. 15, was prepared by diluting a stock solution (31) fivefold with water. GVB2`was VBS with 0.1% gelatin, 0.15 mM CaCI2 and 1.0 mM MgCI2 DGVB2+ was veronal buffer, pH 7.4, U = 0.07, containing 2.5% dextrose, 0.1% gelatin, 0.15 mM CaCl2, and 1.0 mM MgCl2). EDTA/VBS was prepared by mixing 9 vol of VBS with 1 vol of 0.1 M EDTA.
Complement and complement components. Guinea pig C2 was purchased from Diamedix Laboratories (Miami, FL). Human serum depleted of C2 (C2D-HS) was purchased from Cytotech (San Diego, CA). Fresh frozen guinea pig serum diluted 1:40 in EDTA/VBS was used as a source of C3 and C5 through C9.
Detection ofAb binding to antigen by Cl fixation. The Cl fixation and transfer assay was performed as described previously (5, 6) . Briefly, a fixed amount of PNM, pronase-treated PNM, or liposomes was incubated overnight at 4°C with different amounts of human serum diluted in EDTA/VBS to a final volume of 500 ,l. The antigen was washed three times with 1 ml of GVB2' by centrifugation in a Sorvall microfuge at 4°C for 5 or 15 min at full speed. The pellet was resuspended in 300 ,ul ofC2D-HS (as a source ofexcess C 1) diluted 400-fold with GVB2 , then incubated for 30 min at 37°C. After washing, the antigen slurry, now carrying specific Ab and Cl was incubated with sheep erythrocytes carrying anti-Forssman Ab, C4b, and C3b for 15 min at 30°C. Incubations were further carried out first with excess guinea pig C2 then with EDTA-treated guinea pig serum as a source of C3, C5-C9. Lysis ofcells was determined spectrophotometrically, and levels of Ab against PNM or specific lipid fractions were calculated as previously described.
Antigen preparation. PNM was isolated on a discontinuous sucrose gradient by the method of Norton from human dorsal and ventral spinal nerve roots obtained at autopsy within 12 h of death (32) . Ab binding was detected by Cl fixation against native myelin or myelin treated with pronase (Streptococcus greseus; Calbiochem-Behring Corp., La Jolla, CA) in a 20 to 1 protein enzyme (wt/wt) ratio for 2 h at 37°C, followed by incubation with 2 mM PMSF and extensive washes. Pronase treatment resulted in loss of greater than 92% of myelin protein as determined by a modified Lowry assay (33) .
Lipid fractions were prepared as previously described from human sciatic nerve (16) . Briefly, lipids were extracted overnight at room temperature in chloroform/methanol/water, 1:1:0.1 (vol/vol/vol) followed by chloroform/methanol (2:1). The combined lipid extract, adjusted to have a final solvent proportion of chloroform/methanol 2:1, was partitioned into two phases by addition of 0.2 vol of water and the lower phase was further partitioned into five fractions (designated fx Liposome preparation. Each lipid fraction was used to make liposomes as previously described (36) . Briefly, 100 ,ug, dry weight, of fractions 1 through 5, and 50 Mtg of fractions 6 through 9d were each solubilized in chloroform methanol (2:1), and combined with 4 Amol of egg lecithin and 3 Amol of cholesterol. The lipids suspended in a total volume of 500 Al were dried in a conical glass tube while rotating the tube in order to make a thin lipid film on the wall of the tube. DGVB2+ and acid washed glass beads were added to the tubes and vortexed vigorously. The liposomes were washed by centrifugation in a Sorvall microfuge after the addition of 1 ml ofGVB2+ and resuspended in 1 ml GVB2". 20 Ml of each liposome preparation was used in the Cl fixation and transfer assay for detection of Ab binding. The control liposomes contained egg lecithin and cholesterol.
Detection ofantibody binding to lipids on thin layer chromatography plates. Lipids were applied to Merck HPTLC aluminum backed silica gel 60 plates (Applied Analytical Industries, Wilmington, NC), and separated with a solvent system made of chloroform/methanol/ 0.25% CaCl2, 5:4:1 (vol/vol/vol). The front was allowed to migrate 9
cm from the origin. The plates were dried, soaked for 45 s in 0.05% poly isobutylmethacrylate (Polysciences, Inc., Warrington, PA) in nhexane and allowed to dry. The plates were first incubated with 1%
BSA in BSA/PBS for 3 h at 4VC and then with appropriately diluted GBS patient or control serum diluted in BSA/PBS overnight at 4VC. The plates were washed seven times by immersion in 20 ml of PBS for 1 min. Binding of Ab was detected by incubating the plate for 2 h at 4VC with a peroxidase-labeled goat IgG against the M-chain of human IgM (Organon Teknika, Malvern, PA) diluted 1:1,000 in BSA/PBS. The plate was again washed six to seven times. Binding of peroxidaselabeled Ab was detected with a reagent containing 4-chloro-I-naphthol (Bio-Rad Laboratories, Richmond, CA) and hydrogen peroxide as previously described (37) . Color was allowed to develop for 5-20 min and the reaction stopped by washing three times with PBS.
Results
Cl fixation by GBS serum Ab to PNM and pronase-treated PNM. Dose-response curves generated by incubating the PNM with varying amounts of serum from two selected GBS patients are shown in Fig. 1 . Cl fixation is indicated by the lysis ofthe 1.5 X 107 EAC43 cells as described (5, 6) . Since the lysis of erythrocytes in this assay directly reflects the fixation of a single limiting complement component, Cl, the lysis curves are monotonic rising straight from the origin (38) (39) (40) (41) . Both GBS patients in Fig. 1 have a similar Ab titer, as determined by the initial slope of the dose response curve. The lipid nature of these antigen(s) was suggested since as seen in Fig. 1 , GBS serum retained a substantial amount of reactivity to pronase treated PNM even though > 90% of the myelin protein was destroyed enzymatically. No specific fixation was noted in control serum against either the native or modified PNM antigen. Anti-PNMAb binding to lipidfractions reincorporated into liposomes. To determine which class of myelin lipid is bound by anti-PNM Ab, GBS serum was screened for reactivity to lipids fractionated on the basis of partitioning and solubility and reincorporated into artificial lipid membranes of egg lecithin and cholesterol. As seen in Fig. 2 Titers of complement fixing Ab to fraction 8A neutral glycolipids (NGL) were determined in 10 GBS patients. Fraction 8A was further purified from fraction 8 (see methods). Titers in all acute-phase GBS patients studied were significantly elevated (50-220 U/ml) over six disease controls (0-5 U/ml) and 9 normals (0-6 U/ml) (Fig. 3 ). Disease controls included two patients with systemic lupus erythematosus, one with rheumatoid arthritis, one with brachial plexopathy, and one with sarcoidosis. In 3 of 10 GBS patients, the anti-NGL Ab titers were much lower than their anti-PNM Ab titer. To determine the relationship between anti-NGL Ab and anti-PNM Ab in these patients, two different GBS sera, one whose anti-NGL titer correlated well with the anti-PNM Ab titer and one that did not, were absorbed three times overnight at 4°C with either an equal volume of pelleted NGL-liposomes (fraction 8A) or control liposomes and the residual anti-PNM Ab titer determined. As seen in Fig. 4 , absorption by NGL-liposomes resulted in the loss of 85% ofthe anti-PNM Ab activity from the GBS serum in which both Ab fraction 8A lipids separated on thin-layer chromatography plates. Ab binding was detected with peroxidase-labeled goat anti-human IgM (u-chain specific). In six of the eight GBS patients studied in this manner, significant binding of IgM over control was found to a single minor lipid band offraction 8A migrating just anterior to neolactohexaosyl (nLcOse6) ceramide but significantly behind paragloboside (Fig. 5) . In four GBS patients examined no significant binding was seen to any of the PNM gangliosides run in parallel (data not shown). Some fainter binding was also noted to some rapidly migrating unidentified lipid bands contaminating the crude ganglioside fraction. No significant staining was seen with control serum (Fig. 5) . Incubation of a single GBS patient's plasma with extracts of human and dog sciatic nerve as well as a series of neutral and acidic glycolipids standards (Fig. 6) showed binding of IgM, primarily, to single glycolipid bands in both dog and human nerve. Although migration of these two bands were similar, the Rf of the human band was slightly slower suggesting some possible differences between the two molecules. With lower dilutions of the primary (< 100-fold) and ally with liposomes containing either 50 Ag, dry weight, fraction 8A (see text), 4 Amol of egg lecithin and 3 .mol cholesterol or lecithin and cholesterol alone. Percent loss of anti-PNM Ab activity was calculated on the basis of the anti-PNM Ab activity of the same serum during serial absorption with control liposomes, as 100%. Only 20% of Ab activity could be depleted in one serum (o) while most of the anti-PNM Ab activity was depleted in the second GBS serum (v). Plasma dilution from lanes G-K was 100-fold and for lanes L-Q it was 75-fold. Glycolipids in lanes A-E were detected by orcinol spray. (Table I) while absorption by control liposomes did not significantly alter the anti-PNM Ab titer. In seven other GBS sera 18-97% ofanti-PNM Ab activity and 80-100% of anti-NGL activity was absorbed by Forssman-liposomes (Table I) Fig. 8 . In all 12 GBS sera studied titers of anti-Forssman Ab (54 and 272 U/ml) were significantly elevated over 12 disease controls (0 to 22 U/ml), (Table I) and decreased over time, in a manner similar to the fall in anti-PNM Ab. Two of the disease controls (anti-Forssman titers, 20 and 22 U/ml) were significantly higher than anti-NGL Ab titers (0 and 4 U/ml, respectively). Binding ofa monoclonal Ab against Forssman antigen to a NGL of human peripheral nerve. A rat hybridoma IgM Ab, MI/87.27.7 (ATCC), specific for Forssman antigen (43) bound both Forssman glycolipid, purified from sheep erythrocytes and a single band of the NGL fraction, 8A of human PNM separated on HPTLC plates (Fig. 9) but not a series of neutral and acidic glycolipids. Binding was similar to that of IgM serum Ab of GBS patients (Figs. 5 and 6 ). No binding was seen in the absence ofprimary Ab or with a rat IgM monoclonal Ab without specificity for sheep erythrocyte Forssman.
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Discussion
Anti-PNM Ab in GBS serum binds human PNM and activates complement, thus generating COb-9 presumably one of the effectors in peripheral nerve demyelination (7) (8) (9) . Previous studies did not show in a consistent manner antibodies to any PNM component (27, 28) , even though both proteins and lipids known to induce inflammatory demyelination in experimental animals such as P2 and galactocerebroside (18, 19) were included as antigens. In view of the finding that complement fixing Ab that react to normal PNM are consistently present in acute-phase GBS serum (5, 6), we wanted to know the specific antigen(s) of PNM that these anti-PNM Ab reacted to, as well as the heterogeneity of their reactivity.
As shown in Fig. 1 corporated into artificial membranes as antigen targets in the Cl fixation and transfer assay. Ab binding from GBS patient serum was consistently greatest to lipid fraction 8A (Figs. 5 and 6) isolated from human peripheral nerve. Based on the fraction's migration on HPTLC plates, it contained neutral glycolipids with 4 to 6 carbohydrate residues. Lower but definite Ab-mediated Cl fixation was also noted to fractions 3 and 4 ( Fig. 2) of the Folch lower phase lipids which also contained neutral glycolipids but with fewer carbohydrate residues and were eluted from Unisil column with acetone and acetone/ methanol (9:1), respectively. Reactivity to fraction 3 and 4 although much. less may be due to cross-contamination of fractions by NGL, reactivity to multiple antigens, or possible recognition of a shared epitope.
Demonstration of more than one reactivity on the solid phase overlay of thin-layer plates with two of four GBS patients' sera (data not shown) would suggest one of the latter two possibilities.
As shown in Fig. 3 , all 10 GBS patient sera screened showed significant Ab-mediated Cl fixation to fraction 8A neutral glycolipids reincorporated into liposomes. Titers-of GBS patients varied between 50 and 220 U/-ml and were significantly elevated over six disease controls (0-5 U/ml) and nine normal controls (0-6 U/ml). In the sera of 3 of 10 GBS patients, titers against the neutral glycolipid fraction appeared to be significantly lower when compared to the total anti-PNM Ab titers (Table I) . Absorption by fraction 8A-liposomes of serum of one of these three (Fig. 4) resulted in the loss of only 20% of the anti-PNM Ab activity which contrasted sharply with the near complete absorption of a second GBS serum anti-PNM Ab. This data suggested that anti-PNM Ab ofsome OBS patients recognize more than one antigen ofPNM, one of which was contained in fraction 8A. Multiple or different antigens, with different densities on the myelin surface was previously suggested by the more rapid plateau at higher serum concentrations of Cl fixation by serum of some GBS patients with similar anti-PNM Ab titers when PNM of the same source and amount was used as an antigen (data not shown).
Fraction 8A contained four neutral glycolipid bands detected with orcinol on a thin layer chromatography plate (Fig.   5 ). The IgM Ab of six of the eight GBS sera bound a single orcinol positive band that migrates just anterior to neolactohexaosylceremide, but behind paragloboside containing four carbohydrates (Figs. 5 and 6 ). Binding was detected with a peroxidase-labeled goat anti-human IgM Ab, unchain specific. Some faint but definite Ab binding to this same band was also seen with 3 of 10 normal controls on the solid phase overlay but was significantly less than that seen with the GBS patients.
Binding of IgM from a GBS patient could also be detected to similar glycolipid, Forssman antigen isolated from dog sciatic nerve (Fig. 7) and sheep red blood cells (data not shown) but not a variety of other neutral and acidic glycolipids. Interestingly, titers of complement fixing Ab to Forssman antigen in GBS serum were significantly elevated over normal and disease controls (Fig. 8) . Antigenic cross reactivity between NGL of fraction 8A, Forssman and human PNM was suggested by similar absorptions of serums of 8 GBS patients with liposomes containing Forssman purified from sheep erythrocytes (Fig. 7, Table I ). These absorptions resulted in the loss of 86-100% of anti-NGL Ab activity and 17-97% of anti-PNM Ab activity. No similar activity losses were seen with absorptions by control liposome alone (Fig. 7) . Antigenic cross-reac-tivity was further suggested by binding of a monoclonal Ab specific for Forssman hapten (43) to a band oflipid fraction 8A of human nerve on a HPTLC plate (Fig. 9) .
Forssman antigen is widely distributed in nature being a component of several viruses, bacteria, parasites, and the cell membranes of certain mammalian species including rodents, cats, sheep, and dog (44) . Although the human species is generally considered to be Forssman negative, Forssman antigen was identified by Ab binding in the gastrointestinal mucosa of 30% of patients and in certain human tumors of the intestine, lung, and skin (44) (45) (46) (47) . Data of our absorption experiments suggest that Forssman or a cross-reacting glycolipid is a component ofhuman PNM and that Ab to this myelin component is a portion in some and the primary component in other patients of the anti-PNM Ab that correlates with the development of peripheral nerve demyelination in GBS (5, 6) . Differences in mobility on chromatographic plates (Fig. 7) and lack of correlation between Ab titers to the myelin neutral glycolipid and Forssman antigen in some disease control serum suggested the antigenic structures of these two lipids were not completely identical.
Ab to Forssman antigen are part of heterophile responses that represent a series of cross-reacting antibodies that can frequently recognize carbohydrate determinants (44) . Serum heterogenic antibodies including Forssman are reported to occur in 30-66% of normal humans but at generally lower serum concentrations than we are reporting (47, 48 Relatively high titers of anti-Forssman Ab were reported in normal individuals using a liposome, marker release assay without consideration of the background release, by serum, of marker from liposomes without the glycolipid (48) . In the current study, 24% of 25 normal laboratory workers had measurable titers of anti-Forssman Ab which varied from 0 to 11 U/ml (Fig. 8) .
Forssman Ab responses are associated with disease production of an arthus response in guinea pig (50) 
